ECO and Agrinnovation (Yissum) LP sign swine antimicrobial novel formulation development & licensing deal
3 December 2019
ECO AH and Agrinnovation (Yissum) LP sign swine antimicrobial novel formulation development & licensing deal
ECO Animal Health Ltd (ECO), a wholly owned subsidiary of ECO Animal Health Group plc, is pleased to announce that it has entered a development and licensing deal with Agrinnovation and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., State of Israel.
This deal, based on a number of milestone payments, allows ECO to licence patented research related innovations leading to the development of a unique long acting injectable florfenicol product to treat swine bacterial respiratory disease with a single dose. Florfenicol is an antimicrobial used only in veterinary medicine and the product will complement both the spectrum of activity and the oral route of administration of Aivlosin®, ECO’s patented molecule for the treatment of economically important diseases in pigs and poultry.
Peter Lawrence, Non-executive Chairman of ECO Animal Health Group plc said:
“Recent market research has indicated that treatment for respiratory disease accounts for over 40% of antimicrobial treatments in finishing pigs. We are delighted to have entered this collaboration with Agrinnovation.”
Dr. Ido Schechter, Agrinnovation CEO said:
“We are excited to enter this collaboration with ECO, which underscores the promise of agricultural research at Hebrew University and supports our vision of sustainable agriculture around the world through collaborations between industry and academic organizations.”